GSK and PFE Related Headlines
Go Back- ViiV Healthcare announces U.S. FDA approval of Dovato for adolescents living with HIV (GSK) (PFE)
- ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
- ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals
- ViiV Healthcare and The American Academy of HIV Medicine Announce Fellowship to Improve HIV Prevention in Key Communities
- ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
- ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV
- ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine)
- ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine)
- Ideaya Biosciences (IDYA) Mentioned Positively at Citi, 'developing into an attractive takeout candidate'
- Pfizer RSV vaccine lags GSK’s as head-to-head competition underway
- ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023
- GSK sues Pfizer in US for patent infringement over RSV vaccine
GSK and PFE Related Press Releases
Go Back- ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
- ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals
- ViiV Healthcare and The American Academy of HIV Medicine Announce Fellowship to Improve HIV Prevention in Key Communities
- ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
- ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV
- ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine)
- ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine)
- ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023
